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Human tuberculosis remains a significant cause of mortality and morbidity throughout the world. The
global economic impact of bovine TB is considerable. An effective vaccine would be the most cost-
effective way to control both epidemics, particularly in emerging economies. TB vaccine research
would benefit from the identification of an immune correlate of protection with which vaccines could be
gated at both preclinical and clinical levels. In-vitro mycobacterial growth inhibition assays (MGIA) are
functional assays that include most aspects of the complex host immune response to mycobacteria, and
they may serve as functional immune correlates for vaccine development. We applied to cattle an MGIA
that was developed for use with human and murine samples. Several technical difficulties were
encountered while transferring it to the cattle model. However, our data demonstrate that the assay was
not discriminatory in cattle and further work is needed before using it for bovine TB vaccine
development.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Tuberculosis (TB) remains amajor problem for both humans and
bovines. In 2015, 1.4 million people died of TB [1] and more than
32,000 animals were slaughtered in Great Britain alone due to the
test and slaughter policy used in developed countries to control
bovine TB (bTB) in cattle [2]. There is also a considerable economic
impact of bTB worldwide including in developing countries where
bTB has zoonotic implications since Mycobacterium bovis (M. bovis)
can cause TB in humans, particularly when unpasteurised milk is
consumed. The main causative agent of bTB is M. bovis, a close
relative of Mycobacterium tuberculosis (M.tb). M. bovis is also the
source of the only licenced vaccine against TB [3], M. bovis bacillusBambino Gesù, Laboratorio di
ergata, Facolta di Medicina e
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r Ltd. This is an open access articleCalmette-Guerin (BCG), which was attenuated from a cattle isolate
of M. bovis. BCG is widely used in humans throughout the world as
it does confer consistent and reliable protection against severe
forms of TB in infants, although protection against pulmonary TB in
adults is highly variable [4]. BCG vaccination of cattle has shown a
comparable degree of protective variability, both at population and
individual animal level, as seen in humans [5]. Currently, a leading
approach in bovine and human TB vaccine research is the devel-
opment of a boosting agent that will improve and prolong the
immune response induced by BCG [6]. There are many reasons why
it is advantageous to address bTB and human TB in parallel. Inter-
disciplinary collaborations will expand our knowledge with the
information available from human, animal and environmental
studies. Human and animal health are connected, as demonstrated
by the existence of zoonoses.
In the absence of an immune correlate of protection with which
to accelerate vaccine design and evaluation, vaccine development is
costly and time-consuming. Protection against M. tb is likely to be
multifactorial. An in vitro functional assay that measures the sum of
the parts of a host immune response might have utility as a
correlate of protection. In vitro mycobacterial growth inhibition
assays are currently being developed and evaluated as a potential
immune correlate for human TB vaccine research [7] and resultsunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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The parallel development, in humans and animals, of an assay such
as a mycobacterial growth inhibition assay (MGIA), will help us
understand more about the models and the similarities and dif-
ferences between species and their immune systems.
MGIA could prove useful for the evaluation of vaccine-induced
protection and could ultimately reduce or even replace lengthy,
costly M. bovis or M. tb infection experiments in cattle and other
animal models, thus fulfilling the 3Rs principle to replace, reduce
and refine the use of animals in scientific procedures (https://www.
nc3rs.org.uk/).
Therefore, following a translational approach, we selected a
BACTEC-MGIT based MGIA, originally developed by Cheon et al.
[10] which had already been optimised for mice and humans [7,9].
The assay was adapted and evaluated for the assessment of BCG
vaccine efficacy by measuring mycobacterial survival after incu-
bation with bovine whole blood (WB) or PBMC.
2. Materials and methods
2.1. Cattle
Holstein-Friesian male cattle (approximately 6 months of age at
the beginning of study) were recruited from officially TB-free farms
in Great Britain. All animals were housed at the Animal and Plant
Health Agency (APHA) at the time of blood sampling, and proced-
ures were conducted under the remit of a United Kingdom Home
Office license according to the Animals (Scientific Procedures) Act
of 1986 (amended) and were approved by the local animal welfare
ethical review board (APHA-AWERB).
2.2. PBMC isolation
PBMCwere isolated from heparinised blood by density-gradient
centrifugation with Histopaque® (Sigma) according to manufac-
turer's instructions.
2.3. Bacterial strains
Animals were vaccinated with approximately 1 million CFU of
BCG Danish (SSI, Denmark), prepared according to manufacturer's
instructions, and challenged in vivowith 8000 CFU ofM. bovis strain
AF 2112/97. For the in vitro challenge performed within the MGIA,
BCG Pasteur grown in-house with 7H9 medium was used (titre:
1.4  106 CFU/mL).
2.4. Whole blood and PBMC MGIA
The protocol was adapted from a previously published human
MGIA protocol by Fletcher et al. [7]. Briefly, either 300 mL of blood or
1 million PBMC in 300 mL of RPMI medium were added, in a 2 mL
tube, with 300 mL of RPMI medium containing 1.167  104 CFU/mL
of BCG Pasteur. Based on reference monocyte values for 6e12
month old bovines, this dose translated into an approximate MOI of
1:51 ± 17 for WB and 1:6 ± 1 for PBMC MGIA. WB or PBMC were
incubated at 37 C on a rotating platform for 90e96 h and lysed
with sterile water. The lysate was transferred to Bactec MGIT sup-
plemented with PANTA antibiotics and acid-albumin-dextrose-
catalase (OADC) enrichment broth (all from Becton, Dickinson)
and incubated in a Bactec MGIT 960 until detection of growth. The
conversion of the TTP into CFU was achieved by means of a stan-
dard curve (data not shown). All samples were run in duplicate.
Each experiment included duplicate control tubes inoculated with
2.5 mL of BCG stock, equivalent to 3500 CFU/tube, to monitor stock
viability. A time to positivity (TTP) of 7 days was chosen asinoculum dose and the average TTP of the control tubes for all
experiments was 169.8 h.
2.5. Flow cytometry
For PBMC surface staining, cells were incubated with LIVE-
DEAD® Fixable Yellow Dead Cell Stain (YeViD, Invitrogen) and with
a-CD3-Alexa488 (Monoclonal Antibody Center), a-bovine d chain-
Alexa405 (Kingfisher Biotech, Inc.), a-CD335-PE (AbD Serotec)
and a-CD14-Alexa700 (BIO-RAD). All antibodies were bought un-
conjugated and labelled as indicated with the appropriate Zenon
label (Life Technologies™), according to manufacturer's in-
structions. Prior to acquisition, cells were washed and fixed.
2.6. Statistical analyses
All statistical analyses were performed using GraphPad Prism
(Graph-Pad, USA) with a non-parametric one-way ANOVA (Krus-
kall-Wallis) followed by Dunn's test of multiple comparison. Cor-




In order to adapt the assay to bovine samples we performed
some optimisation experiments. Factors such as the temperature of
blood storage following venesection and prior to processing forWB
assays or the processing steps for PBMCwere addressed to improve
reproducibility. Briefly, to optimise the WB assay, whole blood was
incubated at different temperatures (4 C, RT and 37 C) for up to
4 h before commencing the assay and the results showed no sig-
nificant differences related to storage temperature. PBMC MGIA
revealed an inconsistency in the number of CFU recovered from
replicates, but this was improved by eliminating a centrifugation
step which followed cell lysis. The protocol was modified accord-
ingly (Supplementary Fig. SF1 and Supplementary Table ST1).
3.2. MGIA evaluation
To assess the potential of the MGIA to reveal differences in the
control of mycobacterial growth between BCG-vaccinated and
naïve animals, the assay was evaluated using samples from 24
animals, 12 vaccinated subcutaneously with BCG Danish SSI and 12
naïve controls. Fig. 1 shows the experimental schedule (Panel A)
and the result of theMGIA obtainedwith bothWB and PBMC (Panel
B and C, respectively).
Blood samples were taken at 2, 6, 9, 12 and 14 weeks after BCG
vaccination and employed in the WB-MGIA. At the same time,
PBMC were isolated and stored. When all samples had been
collected, PBMC from all time points were thawed and employed in
a single experiment. In Fig. 1B and C, each symbol corresponds to a
single animal. No significant difference in mycobacterial growth
was detectable between BCG-vaccinated and naïve animals, using
either WB or PBMC at any time-point assessed. WB-MGIA resulted
in similar CFU numbers between the two groups for all time points
analysed. In the case of PBMC-MGIA, CFU recovery decreased for
BCG-vaccinated animals at weeks 9 and 12, but this trend towards
higher growth inhibition in vaccinated calves compared to BCG-
naïve animals was statistically not significant. Interestingly, in WB,
a significant decrease in mycobacterial growth inhibition, irre-
spective of whether the animals were vaccinated or not, between
early sampling times (week 2) and later tests (weeks 9, 12, 14) was
found (Fig. 1B). This was not observed in PBMC (Fig. 1C).
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PBMC samples used in the assay were also analysed by flow
cytometry in order to identify potential cell populations likely to be
involved in mycobacterial growth inhibition. Antibody panels used
contained markers for T lymphocytes (CD3), monocytes (CD14),
gamma delta (gd) T cells and natural killer (NK) cells (gating
strategy described in Supplementary Fig. SF2).
Individual cell percentages were analysed against the result of
the MGIA. Fig. 2 shows the relationships between the PBMC-MGIA
and the cell subsets characterised at weeks 6 and 9 combined.
These time-points were selected in order to focus on the immune
response pre-challenge (for technical reasons not all data for week
2 were available). The results for monocytes, gd T cells, NK cells and
NK T-like cells are shown. A significant correlation was found only
between the proportions of NK T-like cells (CD3þCD335þ) and the
extent of growth inhibition in vitro, i.e. the higher the proportion of
NK T-like cells present in the sample, the less CFU were recovered
in the MGIA (Fig. 2).4. Discussion
In this study, we applied a mycobacterial growth inhibition
assay to bovine samples from BCG-naïve and BCG-immunised
calves to assess the discrimination potential it could afford in this
animal model.
The literature describes several attempts to develop an in vitro
growth inhibition assay to estimate immunity against mycobac-
teria. Silver et al. had developed a cell-based assay where M. tb
growth inhibition was achieved in infected monocytes incubated
with autologous non-adherent cells from peripheral blood of both
PPD-positive and PPD-negative healthy subjects [11]. A similar
approach, although based onwhole blood, showed that tuberculin-
positive individuals were better at controlling growth of intracel-
lular BCG lux than tuberculin-negative counterparts [12]. Wallis
et al. employed the WB assay to measure the bactericidal potential
of drugs combined with immune mechanisms of TB-naïve healthyFig. 1. Evaluation of the vaccine-effect detection level afforded by the assay. Panel A: tim
consecutive time points. Symbols represent single animals and bars show the mean and stan
all 24 animals as one group. Black squares on panel B, WB-MGIA, represent the assay intern
immunisation is based on 12 animals only, 6 BCG-vaccinated and 6 controls. Statistical ana
p < 0.05; **: p < 0.01; ****: p < 0.0001.subjects [13]. The innovation of his work included the use of the
Bactec MGIT detection system based on liquid cultures instead of
standard agar plates. Our work was based on the same detection
system while the protocol had to be adjusted to suit our purpose.
Optimisation experiments were carried out to minimize the
variability seenwhen using PBMC instead ofWB in theMGIA. Assay
variability was observed also by Fletcher et al. [7] who found that,
for a human MGIA, variability was higher when using WB
compared to PBMC. However, the variability in the human MGIA
study referred to repeated sampling over time. One of the reasons
suggested to explain this variability was the processing of WB in
different experiments, while cryopreserved PBMC could be pro-
cessed simultaneously. The variability between replicates in our
PBMC assay could be improved by modifying the test protocol. In
WB, we observed differences in MGIA results between different
bleed time points rather than between replicates. This cannot be
accounted for by assay variability as the positive control tubes used
in every assay were giving highly consistent results between
different experiments (Fig. 1, panel B, black squares and line). The
WB-MGIA variability between sampling time points manifested
itself as higher growth inhibition at early bleeds, which was
reduced at later bleeds (week 9 and after, Fig. 1B). This could be due
to different levels of innate immune cell numbers or functionality
in these animals at earlier time points when the immune system of
these young calves is still being re-modelled. This intensive innate
immune system re-modelling in the first 6 months of age is a
common observation in ruminants, particularly in the number of gd
T cells and NK cells [14]. This may have less of an impact using the
more standardised approach of PBMC-MGIA. Unfortunately, we
were unable to detect a significant difference in growth inhibition
between BCG-immunised and BCG-naïve animals using either the
WB- or PBMC-MGIA.
This is consistent with the findings of Carpenter et al. who used
a cellular MGIA involving the addition of autologous lymphocytes
to BCG-infected macrophages, and found no difference in the
ability to inhibit mycobacterial growth between naïve and BCG-
vaccinated cattle [15]. However, it is in contrast to previouse line for animal immunisation and blood withdrawal. Panel B: WB- and PBMC-MGIA at
dard deviation. Statistical significance between time points was calculated considering
al positive control. Due to technical issues, the results for PBMC-MGIA at week 2 post-
lysis: non-parametric 1 Way ANOVA followed by Dunn's multiple comparison test. *:
Fig. 2. Correlation at week 6 and 9 post-BCG immunisation, of PBMC-MGIA with characterised immune cell populations. PBMC-MGIA (Fig. 1) and cell frequencies were
correlated to highlight which cell population might have a stronger impact on mycobacterial growth inhibition. Correlation strength was evaluated by means of the Spearman rank
correlation coefficient (Spearman r).
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findings of Denis et al. using an expanded PBMC-MGIA [16], which
all showed a significant enhancement of growth inhibition
following BCG vaccination.
The demonstration of a known BCG vaccine effect using this
assay would biologically validate the assay. The lack of detection of
a vaccine effect in the study reported might indicate that uniden-
tified environmental parameters such as co-infection with envi-
ronmental mycobacteria or Mycobacterium avium sub.
paratuberculosis (MAP) could have a stronger effect on mycobac-
terial growth inhibition than BCG vaccination. Cattle, in contrast to
specific-pathogen-free mice, are more likely to face constant chal-
lenge by environmental mycobacteria or being infected with MAP,
and our results could therefore be a reflection of this scenario
inherent to non-laboratory animal species. Responses to avian tu-
berculin purified protein derivative (PPD) were found in the control
animals (Supplementary Fig. SF3), which is an indicator of exposure
to environmental bacteria such as MAP. It has been shown that
sensitisation with MAP can impart a degree of protection against
M. bovis challenge [17] and this could be reflected in the lack of
differences between MGIA responses in vaccinated and naïve
calves. The significant inhibition seen in the human assays cited
[7,11,12] could also potentially be explained considering that the
samples tested were all from healthy subjects from developed
countries. It is very unlikely that throughout their lives, those
subjects were constantly challenged by environmental mycobac-
teria as could happen in non-developed countries or to bovines. It is
also possible that reproducibility in mice is higher due to genetic
identity and the controlled environment where they are kept.
However, BCG is known to confer partial protection in cattle against
in vivo M. bovis challenge [18].
As we did not observe a vaccine-associated effect using the
MGIA, and it is likely that innate immune responses have an impact
on in vitro mycobacterial growth inhibition, we analysed four
innate immune cell populations (monocytes, gd Tcells, NK cells andNK T-like cells) in order to investigate a possible association be-
tween the proportions of these cells in PBMC and MGIA reactivity
and we detected a statistically significant association between
MGIA responses and the proportion of NK T-like cells
(CD3þCD335þ) suggesting a role for these cells in the restriction of
mycobacterial growth.
An immune correlate of protection in both the human and
bovine field would be extremely useful. As the response to tuber-
culosis involves several features of the immune system, a functional
assay that measures the sum of the parts could potentially be
game-changing. Considering the synergies between the human and
bovine field, the development of TB vaccines according to a “One
Health” approach could bring many advantages for both. However,
such an immune correlate would need to be sufficiently discrimi-
natory to detect a vaccine effect that correlates with the protection
observed after in vivo challenge, otherwise its benefit would be
limited. We present here our efforts to transfer to the bovine field, a
functional assay that has proven promising for mice and humans.
We found preliminary evidence that NK T-like cells have a role in
in vitro mycobacterial growth inhibition. Unfortunately, we did not
find a significant difference in growth inhibition between naïve and
BCG-vaccinated animals. We also had different reproducibility is-
sues compared to those found in humans. These findings suggest
that the transferability of this assay is not as straight forward as
would be anticipated considering the results obtained in mice and
humans. External factors like pre-sensitisation to environmental
mycobacteria or infection from other pathogens may be con-
founding MGIA results.5. Conclusion
MGIAs have potential as a tool for the evaluation of TB vaccine
candidates at a preclinical and clinical level, by minimising the
number ofM. tb challenge experiments needed and by reducing the
size of TB vaccine clinical trials. Further research is needed to
I. Pepponi et al. / Tuberculosis 106 (2017) 118e122122elucidate the effector mechanisms involved and other factors that
might influence the MGIA in cattle. The establishment of specific
cell populations, which have a role in mycobacterial growth inhi-
bition, together with their mode of action will provide valuable
information for the TB vaccines and biomarkers field.
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